WS07.5 Novel antimicrobial peptides to fight infections in patients with cystic fibrosis von van Eijk, M, van der Ent, C.K, Arets, H.G, Kristensen, M.I, de Cock, H, van Dijk, A, Keijser, B.J, Haagsman, H.P

Volltext

WS14.3 Tobramycin nebulization with the I-neb® in children with cystic fibrosis (TONI study): pharmacokinetics and safety von van Velzen, A.J, Uges, J.W.F, Heijerman, H.G.M, Arets, H.G, Nuijsink, M, van der Wiel-Kooij, E.C, van Maarseveen, E.M, van Zanten, G.A, Pullens, B, Touw, D.J, Janssens, H.M

Volltext

P346 Longitudinal growth patterns; are children with CF still at risk for deprived final height? von Tamer, G., Arets, H.G., Bannier, M.A., van der Ent, C.K., Janssens, H.M., Manaï, B.H., van Santen, H.M., Swolfs, R.J., van der Kamp, H.J.

Volltext

The effect of long term use of rhDNAse on pulmonary colonisation in children with cystic fibrosis von Bonestroo, H, Slieker, M, Arets, H.G

Volltext

Cross-infection of Pseudomonas aeruginosa during an open air meeting on the beach von Ruiter, G, Terlingen, A, Fleer, A, Arets, H.G

Volltext

15 Differences in lung function and physical performance in children with CF: the effect of ACE polymorphisms von Slieker, M.G, Hulzebos, E.H, Arets, H.G, van der Ent, C.K

Volltext

163 Lung disease progression in children with cystic fibrosis von Terheggen/Lagro, S.W, Arets, H.G, van der Ent, C.K

Volltext